Locations

Georgia

Georgia Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of Georgia

Georgia Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

Georgia Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

Georgia Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

Research

Abstract:The goals of this study are twofold: 1) verify and extend an experimental animal model for the study of pancreatic adenocarcinoma in which tumors are induced by the direct implantation of 7, 12-dimethylbenz(a)anthracene; 2) to test other chemicals for their carcinogenic potential when implanted into the pancreas. The morphology and behavior of the tumors will be characterized by correlated light and electron microscopy. Evidence of invasiveness and metastatic capabilities of the tumors will be examined. The cell(s) of origin of the tumors will be sought by studying early stages of tumor induction. The implantation model is well suited for such studies because the focus of carcinogenesis is in the area immediately adjacent to the implant. The implantation model has distinct advantages over those models employing systemic administration of large quantities of carcinogen. These advantages are: 1) the high incidence of tumors (80%); 2) the relatively short induction time (119 days); 3) the absence of primary tumors in other organs; for example, liver, stomach, or lungs; 4) there is no administration of large amounts of carcinogen with its attendant systemic toxicity; and 5) there is no impairment of immune and host defenses by systemic toxicity; and 5) there is no impairment of immune and host defenses by systemic poisoning of the host animal. Tumors developed in this model will be compared with the hamster model and with human pancreatic adenocarcinoma. Several parameters of tumor induction will be investigated, including dosage level, method of implantation, alterations with increasing time, age of animals at the time of implantation, species differences, and the effects of different carcinogens. Validation of the implantation model will make possible further studies directed toward understanding the development of human pancreatic adenocarcinoma. It is anticipated that this model can be studied by methods employing cell culture, transplantation, and chemotherapy. The findings derived from this model should contribute to the general understanding of chemical carcinogenesis.

Tags: Models, Biological, Neoplasms Of Pancreas, Neoplastic Transformation, Carcinogens, Chemical Cyclics, Carbopolycyclics, Benzanthracenes, Dosage And Route, Route Of Administration, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms, Adenocarcinoma, Neoplastic Growth, Neoplasms Invasiveness, Neoplastic Growth, Neoplasms Metastasis, Neoplastic Transformation, Carcinogens, Screening, Tissue Compatibility-transplant, Implant Age (animal), Mammals, Rodents, Myomorpha, Hamsters*, Mammals, Rodents, Myomorpha, Rats (laboratory)*, Optics, Microscopy, Electron Scanning*, Optics, Microscopy, Electron*

  • Followup Grant: 2R26CA022063-03

Abstract:This application requests support to permit Emory University to participate in clinical trials conducted under the auspices of the Eastern Cooperative Oncology Group. This is a multiple disciplined approach involving collaboration between medical and surgical oncologists, radiation therapists, and pathologists. Emory serves as a regional referral center for cancer and over 2500 newly diagnosed patients are seen annually. The objectives of this proposal are to improve therapy of cancer through research and provide a database for scientific questions regarding cancer biology, epidemiology and clinical trials methodology. The specific aims are to increase case accruals to cooperative group protocols and to expand Emory’s participation in the science involved in development of group protocols. Faculty members participate in Group scientific committees. Investigations ongoing at Emory with potential for expansion into group studies are the use of ether phospholipids as purging agents for autologous bone marrow transplantation, the use of calcitonin gene rearrangements for detection of minimal residual disease, combination chemotherapy programs for autologous and allogeneic bone marrow transplantation for lymphomas, hematopoietic growth factors on thrombocytopoiesis, the use of viral oncolysates in melanoma, and the use of cytokine therapy in human colorectal cancer.

Tags: Cancer Prevention, Human Therapy Evaluation, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Genetics, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Therapy Bacillus Calmette Guerin Vaccine, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Androgen Inhibitor, Anthracycline, Antineoplastic, Autologous Transplantation, Biological Response Modifier, Bladder Neoplasm, Bleomycin, Bone Marrow Transplantation, Brain Neoplasm, Breast Neoplasm, Bronchogenic Carcinoma, Calcitonin, Cancer Information System, Cancer Risk, Castration, Cis Platinum Compound, Clinical Study /trial, Colony Stimulating Factor, Colorectal Neoplasm, Combination Chemotherapy, Community Health Service, Cooperative Study, Cyclophosphamide, Cystectomy, Cytosine Arabinoside, Deoxycoformycin, Dyserythropoietic Anemia, Ether, Etoposide, Fluorouracil, Formamide, Gene Rearrangement, Germ Cell Neoplasm, Hairy T Cell Leukemia, Head /neck Neoplasm, Homologous Transplantation, Ifosfamide, Interferon, Interleukin 3, Interleukin 6, Kidney Neoplasm, Leucovorin, Levamisole, Lymphocytic Leukemia, Lymphoma, Melanoma, Melphalan, Mesothelioma, Metastasis, Methotrexate, Mitomycin C, Mitoxantrone, Multiple Myeloma, Nasopharyngeal Neoplasm, Neoplasm /cancer Diagnosis, Neoplasm /cancer Hormone Therapy, Neoplasm /cancer Immunology, Neoplasm /cancer Surgery, Neoplastic Cell, Oat Cell Carcinoma, Osteogenic Sarcoma, Ovary Neoplasm, Phospholipid, Prednisone, Prostate Neoplasm, Rectum Neoplasm, Sarcoma, Tamoxifen, Therapy Compliance, Thrombopoiesis, Thyroid Neoplasm, Tumor Antigen, Urinary Bladder Epithelium, Vincristine Human Clinical Subject, Polymerase Chain Reaction, Tissue /cell Culture

  • Followup Grant: 5U10CA049762-02
  • Followup Grant: 5U10CA049762-03

Abstract:This application requests support to permit Emory University to participate in clinical trials conducted under the auspices of the Eastern Cooperative Oncology Group. This is a multiple disciplined approach involving collaboration between medical and surgical oncologists, radiation therapists, and pathologists. Emory serves as a regional referral center for cancer and over 2500 newly diagnosed patients are seen annually. The objectives of this proposal are to improve therapy of cancer through research and provide a database for scientific questions regarding cancer biology, epidemiology and clinical trials methodology. The specific aims are to increase case accruals to cooperative group protocols and to expand Emory’s participation in the science involved in development of group protocols. Faculty members participate in Group scientific committees. Investigations ongoing at Emory with potential for expansion into group studies are the use of ether phospholipids as purging agents for autologous bone marrow transplantation, the use of calcitonin gene rearrangements for detection of minimal residual disease, combination chemotherapy programs for autologous and allogeneic bone marrow transplantation for lymphomas, hematopoietic growth factors on thrombocytopoiesis, the use of viral oncolysates in melanoma, and the use of cytokine therapy in human colorectal cancer.

Tags: Cancer Prevention, Human Therapy Evaluation, Neoplasm /cancer Genetics, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Therapy Bacillus Calmette Guerin Vaccine, Acute Leukemia, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Androgen Inhibitor, Anthracycline, Antineoplastic, Autologous Transplantation, Biological Response Modifier, Bladder Neoplasm, Bleomycin, Bone Marrow Transplantation, Brain Neoplasm, Breast Neoplasm, Bronchogenic Carcinoma, Calcitonin, Cancer Information System, Cancer Risk, Castration, Chemoprevention, Cis Platinum Compound, Clinical Trial, Colony Stimulating Factor, Colorectal Neoplasm, Combination Chemotherapy, Community Health Service, Cooperative Study, Cyclophosphamide, Cystectomy, Cytosine Arabinoside, Deoxycoformycin, Dyserythropoietic Anemia, Ether, Etoposide, Fluorouracil, Formamide, Gene Rearrangement, Germ Cell Neoplasm, Hairy T Cell Leukemia, Head /neck Neoplasm, Homologous Transplantation, Hormone Therapy, Ifosfamide, Interferon, Interleukin 3, Interleukin 6, Kidney Neoplasm, Leucovorin, Levamisole, Lymphocytic Leukemia, Lymphoma, Melanoma, Melphalan, Mesothelioma, Metastasis, Methotrexate, Mitomycin C, Mitoxantrone, Multiple Myeloma, Nasopharyngeal Neoplasm, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Diagnosis, Neoplasm /cancer Immunology, Neoplasm /cancer Surgery, Neoplastic Cell, Osteogenic Sarcoma, Ovary Neoplasm, Phospholipid, Prednisone, Prostate Neoplasm, Rectum Neoplasm, Sarcoma, Small Cell Carcinoma Of Lung, Tamoxifen, Therapy Compliance, Thrombopoiesis, Thyroid Neoplasm, Tumor Antigen, Urinary Bladder Epithelium, Vincristine Human Subject, Polymerase Chain Reaction, Tissue /cell Culture

Clinical Trials

Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: erlotinib hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information

Condition: Carcinoma, Non-Small-Cell Lung; Mesothelioma
Intervention: Drug: LBH589
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
More Information

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information

Hospitals and Cancer Centers

Dong M. Shin, MD, FACP

Director Clinical and Translational Cancer Prevention Program
Department: Hematology and Medical Oncology
Appointments: 404-778-1900
wci.referrals@emoryhealthcare.org
1365 Clifton Road, Bldg. C Atlanta, GA 30322

John Crane, Inc. v. Jones
S03G1791. , SUPREME COURT OF GEORGIA, November 8, 2004, Decided.

Putzel Elec. Contrs. v. Jones
A06A1039 , COURT OF APPEALS OF GEORGIA, November 22, 2006, Decided

Flowers v. Union Carbide Corp.
A04A1854. , COURT OF APPEALS OF GEORGIA, January 27, 2005, Decided

John Crane, Inc. v. Highsmith
A04A1507. , COURT OF APPEALS OF GEORGIA, November 24, 2004, Decided

John Crane, Inc. v. Jones
A03A0301 , COURT OF APPEALS OF GEORGIA, SECOND DIVISION, July 2, 2003, Decided

Williams v. Flintkote Co.
A02A0782. , COURT OF APPEALS OF GEORGIA, FIRST DIVISION, June 27, 2002, Decided

Kellogg Co. v. Pinkston
A01A1789. , COURT OF APPEALS OF GEORGIA, SECOND DIVISION, December 11, 2001, Decided

Hoffman v. Ac&S, Inc.
A00A2409. , COURT OF APPEALS OF GEORGIA, March 14, 2001, Decided

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

Name (required)

State (required)

Your Email (required)

Phone

Navigation